Corona Remedies IPO

About the company

Corona Remedies Limited is an India-focused pharmaceutical formulation company that develops, manufactures and markets a wide range of medicines related to women healthcare, heart and diabetes care, pain relief, urology, and more. According to the CRISIL Intelligence report, Corona Remedies is the 2nd fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM), with domestic sales rising 16.77% much higher than the industry average of 9.21% for Moving Annual Total (MAT) sales between June 2022 and June 2025. The company offers a diverse portfolio of 71 brands. Out of these, 27 brands account for over 72% of the company’s domestic sales as of June 30 2025, MAT sales. Some of its best-known brands include B-29 (which brings in over ₹100 crore in revenue), Myoril, Tricium, Cortel, Obimet, and Rosuless. Several brands of the company, like Myoril, COR, and Trazer, hold a leadership position and are among the top brands in their respective sub-groups. The company has two manufacturing facilities in Gujarat and Himachal Pradesh with a total installed capacity of 128.54 crore units per annum across 11 production lines as of June 30, 2025. The Gujarat facility is EU GMP and WHO GMP-certified, while the Himachal Pradesh facility is WHO GMP-approved. A new hormone manufacturing facility in Gujarat is expected to start operations in Q1FY27. The company also invested in La Chandra Pharmalab Private Limited, which operates an EU GMP and WHO GMP-certified hormone API manufacturing facility. The company operates in several fast-growing therapeutic areas. A big part of its sales comes from women's healthcare, where the company has a strong position with ₹408.03 crore in sales or 28.56% contribution to MAT June 2025 domestic sales. Next, it has a meaningful presence in cardio-diabetes medicines, which generated ₹333.99 crore (23.38% of sales). Pain management contributed ₹168.44 crore or 11.79% of MAT June 2025 sales. In urology, the brand is not so big but competitive with ₹64.67 crore or 4.53% contribution. The remaining therapies and product categories together contribute ₹453.36 crore or 31.74%, creating a wide and diversified base. The company has a marketing and distribution network of 2,671 medical representatives in 22 states as of June 30, 2025. The distribution network is backed by 22 carrying and forwarding setups and more than 2,000 distributors across India. It targets the "middle of the pyramid" market segment, with specialists and super-specialists contributing 75.75% of prescriptions during MAT June 2025 sales, compared to 60.96% for the overall IPM. The Indian domestic formulation market, valued at approximately ₹2.30 lakh crore in FY25, represents about 2% of the global pharmaceutical market. The market composition has changed; chronic therapies now represent about 55% and acute therapies 45% of the total domestic formulation market as of FY25. The growth in the chronic segment is expected to outpace the overall market at 8.5-9.5% CAGR between FY25 and FY30. Growth in the acute segment is likely to be slower at 7.5-8.5% CAGR during the same period. Women's healthcare presents significant growth opportunities in India. The female population of the country has steadily risen to nearly 49% of the total population, accompanied by improved life expectancy and access to healthcare. The company targets high-growth chronic and sub-chronic therapies that grew at a CAGR of 20.48% between MAT June 2022 and MAT June 2025, much higher than the IPM CAGR of 10.08%. It also has low exposure to the National List of Essential Medications, with 9.76% of total sales under NLEM 2022 compared to 17.51% for the overall IPM, thus assuring greater pricing flexibility. Now, Corona Remedies Ltd is launching its initial public offering (IPO), which consists of an offer for sale of ₹655.37 crore. Its shares will be listed on the NSE and BSE. ### **How to pre-apply for the Corona Remedies IPO?** You can pre-apply for the Corona Remedies IPO on Upstox. The pre-application for this IPO, which means the pre-apply open date, usually begins a day before the IPO opens for subscription. Follow these steps to pre-apply for the IPO: - Login to your Upstox account, using your six-digit PIN - After successfully logging in, click on ‘Discover’ - On the Discover tab, you will find the ‘Invest in IPO’ section - Under the Invest in IPO section, look for the ‘Corona Remedies IPO’ tab and click on it - Now fill in all the required information, like ‘bid price’ and ‘lot size’ - Confirm and click on ‘Pre-Apply’ - Accept the mandate on your UPI app ### **How to apply for the Corona Remedies IPO?** If you are interested in this investment opportunity but unsure how to apply for the Corona Remedies IPO, here are the steps that you need to follow. When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for the Corona Remedies IPO on Upstox: - Log in to your Upstox account, using your six-digit PIN - After logging in, click on ‘Discover’ - On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section - Under the Invest in IPO section, look for the ‘Corona Remedies IPO’ tab and click on it - Now fill in all the required information, like ‘bid price’ and ‘lot size’ - Confirm and click on ‘Apply’ - Accept the mandate on your UPI app ### **How to check Corona Remedies IPO Allotment Status?** When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally completed on the next working day after an IPO closes. Here’s a step-by-step guide on how to check the Corona Remedies IPO allotment status: - Login to your Upstox account, using your six-digit PIN - After logging in, click on ‘Discover’ - On the ‘Discover’ page, you will find the ‘Invest in IPO’ section - Under the Invest in IPO section, you will find the ‘View all’ option - Once you click on ‘View all’, you will be directed to the ‘IPO’ tab - In the ‘IPO’ tab, click on ‘My applications’ - In ‘My applications’, under the History section, your Corona Remedies IPO allotment status will be mentioned

Financial performance (₹ Cr)

Subscription breakup (final, times)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   08 Dec 2025

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   10 Dec 2025

   Last day to place your bid

3. Basis of Allotment

   Completed
   11 Dec 2025

   Share allotment finalised

4. Refund Initiation

   Completed
   12 Dec 2025

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   12 Dec 2025

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   15 Dec 2025

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.